No Data
Hong Kong stock movement | Code-B (02487) rises over 4% CU-10201 (4% minocycline foam agent for external use) has been approved for上市 by the National Medical Products Administration.
Cathay Pacific-B (02487) rose more than 4%, as of the deadline, up 4.14%, closing at 9.8 Hong Kong dollars, with a turnover of 4.0826 million Hong Kong dollars.
SciClone-B (02487.HK): CU-10201 (Topical 4% Minocycline Foam) has obtained approval from the National Medical Products Administration for marketing.
Gelonghui, November 12th | Kedebi-B (02487.HK) announced that the group's CU-10201 (topical 4% minocycline foam) has been approved for marketing by the China National Medical Products Administration. CU-10201 is indicated for the treatment of non-nodular moderate to severe acne and is suitable for use by children aged nine and above and adult patients. CU-10201 is the world's first and only approved topical minocycline for the treatment of acne vulgaris, as well as the first topical minocycline to be approved for marketing with priority review and approval by the China National Medical Products Administration.
Express News | Cutia Therapeutics - Cu-10201 (Topical 4% Minocycline Foam) Obtained Marketing Approval by Nmpa
Cutia Therapeutics CEO Increase Shareholding in Company
Kei Def-B (02487.HK) Chief Executive Officer and Executive Director, Zhang Lele, further increased shareholding.
Grainews November 11th, Ke Di-B (02487.HK) announced that the board of directors received a notice from the company's CEO and executive director, Ms. Zhang Lele, that she purchased a total of 5000 shares of the company's stock with her personal funds on the open market on November 8, 2024, with a total consideration of approximately 0.0493 million Hong Kong dollars. In October 2024, Ms. Zhang purchased a total of 0.028 million shares on the open market, with a total consideration of approximately 0.3439 million Hong Kong dollars. After increasing her shareholding this time, Ms. Zhang has purchased a total of 0.033 million shares, with a total consideration of approximately 0.3932 million Hong Kong dollars, equivalent to the average price per share.
Insiders Give Up CN¥234k As Cutia Therapeutics Stock Drops To HK$11.32
No Data
No Data